×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Pancreatic Cancer

Feature Video
Pancreatic cancer may be one of the more difficult cancers to be diagnosed with. This program discusses the risk factors, symptoms, and different treatments available to patients with pancreatic cancer as well as firsthand experiences and advice from a Pancreatic patient and her husband.
Beth Fand Incollingo
In a phase 3 trial, five-year overall survival was nearly doubled when capecitabine was added to gemcitabine for patients with pancreatic cancer. 
Jason M. Broderick
Algenpantucel-L failed to improve OS for patients with pancreatic cancer in a phase 3 trial. 
Andrew J. Roth
Nurses and oncologists need to give portal vein thrombosis a closer look, according to one oncolgy nurse. 
Sandra Hanner
In the analysis, there was as much as a 92 percent difference in median overall survival (OS) seen between patients treated in randomized controlled trials and "real world" data.
Sonya Collins
Scientists are investigating a host of new treatment types that may change the outlook for those with pancreatic cancer.
Ryan Marotta
Thanks to the NPF, patients with pancreatic diseases can now find healthcare organizations that prove excellent in treating their conditions.
Kerri Kaplan, executive director and chief operating officer of The Lustgarten Foundation
Exciting new treatment options for patients with pancreatic cancer are on the rise, thanks to organizations such as the Lustgarten Foundation.
Silas Inman
This study of Onivyde, 5-FU and leucovorin for the treatment of patients with metastatic pancreatic cancer was presented at the 2016 Gastrointestinal Cancers Symposium.
Silas Inman
The approval was based on data from the phase 3 NAPOLI-1 trial, which demonstrated a 1.9-month improvement in overall survival (OS) with the addition of Onivyde to 5-FU and leucovorin.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other